PARP1 and neoplasm: In the work described here, we used a reanalysis of a genome-wide genetic screen [8] together with a focused siRNA screen and identified and validated a novel genetic determinant of tumour cell PARP inhibitor sensitivity, the ubiquitin ligase CBLC [18].